Characterization of novel and uncharacterized p53 SNPs in the chinese population - Intron 2 SNP co-segregates with the common codon 72 polymorphism

PLoS ONE

Volumn 6, Issue 1, 2011, Pages

  Phang, Beng Hooi ^a   Chua, Hui Wan ^a   Li, Huihua ^a   Linn, Yeh Ching ^b   Sabapathy, Kanaga ^a,c,d  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; GUANINE; NUCLEOTIDE; PROTEIN P53; THYMINE;

3' UNTRANSLATED REGION; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CHINESE; CODON; CONTROLLED STUDY; DNA FLANKING REGION; ETHNIC DIFFERENCE; EXON; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENE INTERACTION; GENE SEGREGATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC CORRELATION; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; INTRON; LATITUDE; LEUKEMIA; LUNG CANCER; MAJOR CLINICAL STUDY; POPULATION GENETICS; SEQUENCE ANALYSIS; SINGAPORE; SINGLE NUCLEOTIDE POLYMORPHISM; UNITED STATES; ASIAN; ETHNIC GROUP; GENETICS; LUNG TUMOR; MALE; RISK; TUMOR SUPPRESSOR GENE;

3' UNTRANSLATED REGIONS; ASIAN CONTINENTAL ANCESTRY GROUP; CODON; ETHNIC GROUPS; FEMALE; GENE FREQUENCY; GENES, P53; HUMANS; INTRONS; LEUKEMIA; LUNG NEOPLASMS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK;

EID: 79251544575     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015320     Document Type: Article

References (40)

1. Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M (2002) TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Review. Oncogene 26(15): 2157-2165.
2. Vousden KH, Lu X (2002) Live or let die: the cell's response to p53. Nat Rev Cancer 2: 594-604.
3. Brosh R, Rotter V (2009) When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 9(10): 701-713.
4. Haupt Y, Maya R, Kazaz A, Oren M (1997) Mdm2 promotes the rapid degradation of p53. Nature 387: 296-299.
5. Watanabe T, Ichikawa A, Saito H, Hotta T (1996) Overexpression of the MDM2 oncogene in leukemia and lymphoma. Leuk Lymphoma 21: 391-397.
6. Küpper M, Joos S, von Bonin F, Daus H, Pfreundschuh M, et al. (2001) MDM2 gene amplification and lack of p53 point mutations in Hodgkin and Reed-Sternberg cells: results from single-cell polymerase chain reaction and molecular cytogenetic studies. Br J Haematol 112: 768-775.
7. Tan J, Zhuang L, Leong HS, Iyer NG, Liu ET, et al. (2005) Pharmacologic modulation of glycogen synthase kinase-3beta promotes p53-dependent apoptosis through a direct Bax-mediated mitochondrial pathway in colorectal cancer cells. Cancer Res 65(19): 9012-9020.
8. Lavin MF, Khanna KK (1999) ATM: the protein encoded by the gene mutated in the radiosensitive syndrome ataxia-telangiectasia. Int J Radiat Biol 75(10): 1201-1214.
9. Moll UM, LaQuaglia M, Bénard J, Riou G (1995) Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumours. Proc Natl Acad Sci USA 92: 4407-4411.
10. The International HapMap Consortium (2003) The Internation HapMap project. Nature 426: 789-796.
11. Wang-Gohrke S, Weikel W, Risch H, Vesprini D, Abrahamson J, et al. (1999) Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations. Br J Cancer 81(1): 179-183.
12. Gemignani F, Moreno V, Landi S, Moullan N, Chabrier A, et al. (2004) A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Germ line polymorphisms of the tumor suppressor gene p53 and lung cancer. Oncogene 23(10): 1954-1956.
13. Biros E, Kalina I, Kohút A, Stubna J, Salagovic J (2001) Germ line polymorphisms of the tumor suppressor gene p53 and lung cancer. Lung Cancer 31(2-3): 157-162.
14. Lehman TA, Haffty BG, Carbone CJ, Bishop LR, Gumbs AA, et al. (2000) Elevated frequency and functional activity of a specific germ-line p53 intron mutation in familial breast cancer. Cancer Res 60(4): 1062-1069.
15. Pietsch EC, Humbey O, Murphy ME (2006) Polymorphisms in the p53 pathway. Oncogene 25: 1602-1611.
16. Whibley C, Pharoah PD, Hollstein M (2009) p53 polymorphisms: cancer implications. Nat Rev Cancer 9(2): 95-107.
17. Siddique MM, Balram C, Fiszer-Maliszewska L, Aggarwal A, Tan A, et al. (2005) Evidence for selective expression of the p53 codon 72 polymorphs: implications in cancer development. Cancer Epidemiol. Biomarkers Prev 14: 2245-2252.
18. Lum SS, Chua HW, Li H, Li WF, Rao N, et al. (2008) MDM2 SNP309G allele increases risk but the T allele is associated with earlier onset age of sporadic breast cancers in the Chinese population. Carcinogenesis 29(4): 754-761.
19. Toyama T, Zhang Z, Nishio M, Hamaguchi M, Kondo N, et al. (2007) Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients. Breast Cancer Res 9: R34.
20. Khadang B, Fattahi MJ, Talei A, Dehaghani AS, Ghaderi A (2007) Polymorphism of TP53 codon 72 showed no association with breast cancer in Iranian women. Cancer Genet. Cytogenet 173: 38-42.
21. Papadakis EN, Dokianakis DN, Spandidos DA (2000) P53 codon 72 polymorphism as a risk factor in the development of breast cancer. Mol Cell Biol Res Commun 3: 389-392.
22. Damin AP, Frazzon AP, Damin DC, Roehe A, Hermes V, et al. (2006) Evidence for an association of TP53 codon 72 polymorphism with breast cancer risk. Cancer Detect Prev 30: 523-529.
23. Mabrouk I, Baccouche S, El-Abed R, Mokdad-Gargouri R, Mosbah A, et al. (2003) No evidence of correlation between p53 codon 72 polymorphism and risk of bladder or breast carcinoma in Tunisian patients. Ann N Y Acad Sci 1010: 764-770.
24. Buyru N, Tigli H, Dalay N (2003) P53 codon 72 polymorphism in breast cancer. Oncol Rep 10: 711-714.
25. Wu X, Zhao H, Amos CI, Shete S, Makan N, et al. (2002) p53 Genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J Natl Cancer Inst 94: 681-690.
26. Wang YC, Chen CY, Chen SK, Chang YY, Lin P (1999) p53 codon 72 polymorphism in Taiwanese lung cancer patients: association with lung cancer susceptibility and prognosis. Clin Cancer Res 5: 129-134.
27. Beckman G, Birgander R, Sjalander A, Saha N, Holmberg PA, et al. (1994) Is p53 polymorphism maintained by natural selection? Hum. Hered 44: 266-270.
28. Dumont P, Leu JI, Della Pietra AC, 3rd, George DL, Murphy M (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33: 357-365.
29. Siddique M, Sabapathy K (2006) Trp53-dependent DNA-repair is affected by the codon 72 polymorphism. Oncogene 25: 3489-3500.
30. Pim D, Banks L (2004) P53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 108: 196-199.
31. Bergamaschi D, Samuels Y, Sullivan A, Zvelebil M, Breyssens H, et al. (2006) iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. Nat Genet;10): 1133-1141.
32. Phang BH, Linn YC, Li H, Sabapathy K (2008) MDM2 SNP309 G allele decreases risk but does not affect onset age or survival of Chinese leukaemia patients. Eur J Cancer 44: 760-766.
33. Chua HW, Ng D, Choo S, Lum SS, Li H, et al. (2010) Effect of MDM2 SNP309 and p53 codon 72 polymorphisms on lung cancer risk and survival among nonsmoking Chinese women in Singapore. BMC Cancer 10: 88.
34. Prosser J, Condie A (1991) Biallelic Apal polymorphism of the human p53 gene (TP53). Nucleic Acids Res 19: 4799.
35. Gu QH, Chen Q, Hu CP, Li YQ, Yang HZ (2007) Study on the relationship between the polymorphism of p53 gene intron 7 and non-small cell lung cancer (NSCLC) and p53 mutation in NSCLC tissues. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 24(3): 319-321.
36. Li YQ, Li YL, Gu H, Ye AH, Wu TS (2005) p53 gene intron 7 polymorphism and its association with oral neoplasms. Zhonghua Kou Qiang Yi Xue Za Zhi 40(5): 386-389.
37. Bourdon JC (2007) p53 and its isoforms in cancer. Br J Cancer 97(3): 277-282.
38. Carlson CS, Eberke MA, Rieder MJ, Yi Q, Kruglyak L, et al. (2004) Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet 74: 106-120.
39. Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21(2): 263-265.
40. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, et al. (2007) PLINK: a toolset for whole-genome association and population-based linkage analysis. Am J Hum Genet 81: 559-575.